Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced inducement grants for a newly hired employee. The grants, approved by the Compensation Committee, include stock options to purchase 1,250 shares and restricted stock units (RSUs) for 1,875 shares of Vor Bio's common stock. These grants were made under the Vor Biopharma Inc. 2023 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
The stock options have a ten-year term and an exercise price of $0.929 per share, equal to the closing price on July 31, 2024. Both options and RSUs will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly (options) or quarterly (RSUs) over the following 36 months, subject to continued employment.
Vor Bio (Nasdaq: VOR), un'azienda ingegneristica clinica di cellule e genomi, ha annunciato concessioni di incentivo per un nuovo dipendente. Le concessioni, approvate dal Comitato per il Compenso, includono opzioni su azioni per l'acquisto di 1.250 azioni e unità azionarie vincolate (RSU) per 1.875 azioni delle azioni ordinarie di Vor Bio. Queste concessioni sono state effettuate nell'ambito del Piano di Incentivo 2023 di Vor Biopharma Inc., in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Le opzioni su azioni hanno un termine di dieci anni e un prezzo di esercizio di $0.929 per azione, pari al prezzo di chiusura del 31 luglio 2024. Sia le opzioni che le RSU verranno maturate in quattro anni, con il 25% che matura dopo 12 mesi e il restante che matura mensilmente (opzioni) o trimestralmente (RSU) nei successivi 36 mesi, soggetto a mantenimento dell'impiego.
Vor Bio (Nasdaq: VOR), una empresa en etapa clínica de ingeniería de células y genomas, ha anunciado concesiones de incentivos para un nuevo empleado. Las concesiones, aprobadas por el Comité de Compensación, incluyen opciones sobre acciones para comprar 1,250 acciones y unidades de acciones restringidas (RSU) para 1,875 acciones de las acciones ordinarias de Vor Bio. Estas concesiones se hicieron bajo el Plan de Incentivos 2023 de Vor Biopharma Inc., en cumplimiento de la Regla de Cotización 5635(c)(4) de Nasdaq.
Las opciones sobre acciones tienen un plazo de diez años y un precio de ejercicio de $0.929 por acción, igual al precio de cierre del 31 de julio de 2024. Tanto las opciones como las RSU se consolidarán durante cuatro años, con un 25% que se consolidará después de 12 meses y el resto consolidándose mensualmente (opciones) o trimestralmente (RSU) durante los siguientes 36 meses, sujeto a la continuación del empleo.
Vor Bio (Nasdaq: VOR)는 임상 단계의 세포 및 유전체 엔지니어링 회사로, 새로 채용된 직원에게 유인 보상을 발표했습니다. 이 보상은 보상 위원회에 의해 승인되었으며, 1,250 주식 매입 옵션과 1,875 주식의 제한 주식 단위(RSU)가 포함되어 있습니다. 이러한 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 Vor Biopharma Inc.의 2023 유인 계획에 따라 이루어졌습니다.
주식 옵션은 10년의 기간과 주당 $0.929의 행사 가격을 가지며, 2024년 7월 31일의 종가와 같습니다. 옵션과 RSU는 4년에 걸쳐 만기되며, 25%는 12개월 후에 만기되고 나머지는 다음 36개월 동안 계속 고용될 경우 매달(옵션) 또는 분기마다(RSU) 만기됩니다.
Vor Bio (Nasdaq: VOR), une entreprise d'ingénierie cellulaire et génétique en phase clinique, a annoncé des attributions d'incitations pour un nouvel employé. Les attributions, approuvées par le Comité de Rémunération, comprennent des options d'achat de 1 250 actions et des unités d'actions restreintes (RSU) pour 1 875 actions de l'action ordinaire de Vor Bio. Ces attributions ont été faites dans le cadre du Plan d'Incentives 2023 de Vor Biopharma Inc., en conformité avec la Règle de Cotation 5635(c)(4) de Nasdaq.
Les options d'achat ont une durée de dix ans et un prix d'exercice de 0,929 $ par action, correspondant au prix de clôture du 31 juillet 2024. Les options et les RSU seront acquises sur une période de quatre ans, avec 25 % acquis après 12 mois et le reste étant acquis mensuellement (options) ou trimestriellement (RSU) au cours des 36 mois suivants, sous réserve d'un emploi continu.
Vor Bio (Nasdaq: VOR), ein Unternehmen für Zell- und Genomengineering in der klinischen Phase, hat Anreizgewährungen für einen neu eingestellten Mitarbeiter angekündigt. Die Gewährungen, die vom Vergütungsausschuss genehmigt wurden, umfassen Aktienoptionen für den Kauf von 1.250 Aktien und eingeschränkte Aktieneinheiten (RSUs) für 1.875 Aktien des Stammkapitals von Vor Bio. Diese Gewährungen wurden im Rahmen des Vor Biopharma Inc. 2023 Incentive Plans gemäß der Nasdaq-Listing-Regel 5635(c)(4) vorgenommen.
Die Aktienoptionen haben eine Laufzeit von zehn Jahren und einen Ausübungspreis von $0.929 pro Aktie, entsprechend dem Schlusskurs vom 31. Juli 2024. Sowohl die Optionen als auch die RSUs werden über einen Zeitraum von vier Jahren fällig, wobei 25 % nach 12 Monaten fällig werden und der Rest in den folgenden 36 Monaten monatlich (Optionen) oder vierteljährlich (RSUs) fällig wird, vorbehaltlich der fortgesetzten Anstellung.
- Vor Bio is attracting new talent with stock-based compensation
- The company has an Inducement Plan in place for new hires
- The grants align employee interests with shareholder interests through long-term vesting schedules
- The stock price of $0.929 per share indicates a low share price, potentially reflecting market challenges
- The small number of shares granted (1,250 options and 1,875 RSUs) suggests scale of hiring or conservative compensation
CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,250 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,875 shares of Vor Bio’s common stock to one newly hired employee. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
The stock options have a ten-year term and an exercise price of
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Investors & Media
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
FAQ
What inducement grants did Vor Bio (VOR) announce on August 2, 2024?
What is the exercise price of the stock options granted by Vor Bio (VOR) on July 31, 2024?
How do the stock options and RSUs vest for the new Vor Bio (VOR) employee?
Under which plan were Vor Bio's (VOR) inducement grants issued?
